StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for SCLX yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $6.37 | $5.98 | -6.12% | 0.0M |
| 05-19 | $6.00 | $5.98 | -0.33% | 0.1M |
| 05-20 | $6.00 | $6.01 | +0.17% | 0.0M |
| 05-21 | $6.01 | $5.92 | -1.50% | 0.0M |
| 05-22 | $5.98 | $6.11 | +2.17% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $8.61M | $30.25M | $25.46M | $14.90M |
Operating Income | $-32.17M | $-346.01M | $-234.92M | $-48.41M |
Net Income | $-45.65M | $-374.05M | $-327.95M | $-44.05M |
EPS (Diluted) | $-6.28 | $-36.48 | $-31.88 | $-9.68 |
Total Assets | $293.63M | $364.98M | $275.88M | $83.75M |
Total Liabilities | $547.71M | $576.73M | $455.60M | $332.74M |
Cash & Equivalents | $3.35M | $4.96M | $878.00K | $4.10M |
Free Cash Flow OCF − CapEx | Not available | $3.68M | Not available | Not available |
Shares Outstanding | 8.49M | 7.03M | 5.95M | 5.50M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.